Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada

被引:218
作者
Kahn, Susan R.
Panju, Akbar
Geerts, William
Pineo, Graham F.
Desjardins, Louis
Turpie, Alexander G. G.
Glezer, Stanislav
Thabane, Lehana
Sebaldt, Rolf J.
机构
[1] McGill Univ, Jewish Gen Hosp, SMBD, Dept Med, Montreal, PQ H3A 2T5, Canada
[2] McMaster Univ, Hamilton Hlth Sci Henderson Site, Hamilton, ON L8S 4L8, Canada
[3] Univ Toronto, Dept Med & Hlth Policy, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON, Canada
[4] Univ Toronto, Dept Management & Evaluat, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON, Canada
[5] Univ Calgary, Foothills Med Ctr, Calgary, AB T2N 1N4, Canada
[6] CHU Quebec, CHUL, Quebec City, PQ, Canada
[7] McMaster Univ, Hamilton Hlth Sci Gen Site, Hamilton, ON L8S 4L8, Canada
[8] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8S 4L8, Canada
关键词
anticoagulants; knowledge translation; medical patients;
D O I
10.1016/j.thromres.2006.01.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Venous thromboembotism (VTE) prophylaxis in acutely ill medical patients has been shown to be safe and effective. Underutitization of this patient safety practice may result in avoidable mortality and morbidity. Objectives: We aimed to determine the proportion of hospitalized, acutely ill medical patients across Canada who were eligible to receive thromboprophylaxis and to evaluate the frequency, determinants and appropriateness of its use. Patients/methods: CURVE is a national, multicenter chart audit of 29 Canadian hospitals. Data were collected on consecutive patients admitted to hospital for an acute medical illness during a defined 3-week study period. Information on demographic and clinical characteristics, risk factors for VTE and bleeding and use of VTE prophylaxis were recorded. The indications for and appropriateness of VTE prophylaxis were assessed using pre-specified criteria based on international consensus guidelines. Multivariable analyses were performed to identify determinants of prophylaxis use. Results: Of the 4124 medical admissions screened over the study period, 1894 patients (46%) were eligible for study inclusion. The most common specified admitting diagnoses were severe infection (28%), COPID exacerbation or respiratory failure (12%), malignancy (9%) and congestive heart failure (13%). Thromboprophylaxis was indicated in 1702 (90%) study patients. Overall, some form of prophylaxis was administered to 23% of all patients. However, only 16% received appropriate thromboprophytaxis. Factors independently associated with greater use of prophytaxis included internist (vs. other specialty) as attending physician (OR 1.33, 95% confidence interval (CI) [1.03, 1.71]), university-associated (vs. community) hospital (OR 1.46, 95% CI [1.03, 2.07]), immobilization (per day) (OR 1.60, 95% CI [1.45, 1.77]), presence of >= 1 VTE risk factors (OR = 1.78, 95% CI [1.35, 2.34]) and duration of hospitalization (per day of stay) (OR 1.05, 95% CI [1.03, 1.071), however, use of prophylaxis was unacceptably tow in all groups. Patients with cancer had a significantly reduced likelihood of receiving prophylaxis (OR = 0.40, 95% CI [0.24, 0.68]). Presence of risk factors for bleeding did not influence the use or choice of prophylaxis. Conclusion: Most patients hospitalized for medical illness had indications for thromboprophytaxis, yet only 16% received appropriate prophytaxis. Efforts should be made to elucidate the reasons that underlie the very low rate of thromboprophylaxis in medical patients and to develop and test strategies to improve implementation of this patient safety practice. 0 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:145 / 155
页数:11
相关论文
共 31 条
[1]  
Ageno W, 2002, HAEMATOLOGICA, V87, P746
[2]  
*AHRQ, 2001, PUBLICATOIN AHRQ
[3]  
ANDERSON F, 2003, J THROMB HAEMOST S1, V7
[4]  
Anderson F.A., 2003, CIRCULATION, V107, P9, DOI [DOI 10.1161/01.CIR.0000078469.07362.E6, DOI 10.1016/S0272-5231(02)00077-1, 10.1161/01.CIR.0000078469.07362.E6]
[5]   A POPULATION-BASED PERSPECTIVE OF THE HOSPITAL INCIDENCE AND CASE-FATALITY RATES OF DEEP-VEIN THROMBOSIS AND PULMONARY-EMBOLISM - THE WORCESTER DVT STUDY [J].
ANDERSON, FA ;
WHEELER, HB ;
GOLDBERG, RJ ;
HOSMER, DW ;
PATWARDHAN, NA ;
JOVANOVIC, B ;
FORCIER, A ;
DALEN, JE .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (05) :933-938
[6]   CHANGING CLINICAL-PRACTICE - PROSPECTIVE-STUDY OF THE IMPACT OF CONTINUING MEDICAL-EDUCATION AND QUALITY ASSURANCE PROGRAMS ON USE OF PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM [J].
ANDERSON, FA ;
WHEELER, HB ;
GOLDBERG, RJ ;
HOSMER, DW ;
FORCIER, A ;
PATWARDHAN, NA .
ARCHIVES OF INTERNAL MEDICINE, 1994, 154 (06) :669-677
[7]   Missed opportunities for prevention of venous thromboembolism - An evaluation of the use of thromboprophylaxis guidelines [J].
Arnold, DA ;
Kahn, SR ;
Shrier, I .
CHEST, 2001, 120 (06) :1964-1971
[8]   The Canadian Adverse Events Study:: the incidence of adverse events among hospital patients in Canada [J].
Baker, GR ;
Norton, PG ;
Flintoft, V ;
Blais, R ;
Brown, A ;
Cox, J ;
Etchells, E ;
Ghali, WA ;
Hébert, P ;
Majumdar, SR ;
O'Beirne, M ;
Palacios-Derflingher, L ;
Reid, RJ ;
Sheps, S ;
Tamblyn, R .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2004, 170 (11) :1678-1686
[9]   Thromboprophylaxis in medical patients: Focus on France [J].
Bergmann, JF ;
Mouly, S .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2002, 28 :51-55
[10]   Managing venous thromboembolism in Latin American patients: Emerging results from the Brazilian Registry [J].
Caiafa, JS ;
de Bastos, M ;
Moura, LK ;
Raymundo, S .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2002, 28 :47-50